Repligen Stock Today
| RGEN Stock | USD 164.35 0.49 0.30% |
PerformanceMild
| Odds Of DistressLow
|
Repligen is selling at 164.35 as of the 4th of January 2026; that is 0.30% increase since the beginning of the trading day. The stock's open price was 163.86. Repligen has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 13th of June 2024 and ending today, the 4th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 1990 | Category Healthcare | Classification Health Care |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. The company has 56.29 M outstanding shares of which 4.12 M shares are at this time shorted by private and institutional investors with about 6.06 trading days to cover. More on Repligen
Moving together with Repligen Stock
Moving against Repligen Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Repligen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Anthony Hunt | ||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Medical Instruments & Supplies, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsRepligen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Repligen's financial leverage. It provides some insight into what part of Repligen's total assets is financed by creditors.
| |||||
Repligen (RGEN) is traded on NASDAQ Exchange in USA and employs 1,778 people. Repligen is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.25 B. Repligen conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 56.29 M outstanding shares of which 4.12 M shares are at this time shorted by private and institutional investors with about 6.06 trading days to cover.
Repligen currently holds about 596.51 M in cash with 175.39 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.75.
Check Repligen Probability Of Bankruptcy
Ownership AllocationThe majority of Repligen outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Repligen to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Repligen. Please pay attention to any change in the institutional holdings of Repligen as this could imply that something significant has changed or is about to change at the company.
Check Repligen Ownership Details
Repligen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Brown Capital Management, Llc | 2025-06-30 | 1 M | |
| Geode Capital Management, Llc | 2025-06-30 | 980.7 K | |
| Conestoga Capital Advisors, Llc | 2025-06-30 | 976.9 K | |
| Holocene Advisors, Lp | 2025-06-30 | 936.8 K | |
| Alliancebernstein L.p. | 2025-06-30 | 906.4 K | |
| Dimensional Fund Advisors, Inc. | 2025-06-30 | 768 K | |
| Impax Asset Management Group Plc | 2025-06-30 | 761 K | |
| Millennium Management Llc | 2025-06-30 | 701.2 K | |
| New York State Common Retirement Fund | 2025-06-30 | 606 K | |
| T. Rowe Price Associates, Inc. | 2025-06-30 | 6.6 M | |
| Blackrock Inc | 2025-06-30 | 6.1 M |
Repligen Historical Income Statement
Repligen Stock Against Markets
Repligen Corporate Management
| Christine Gebski | Senior Chromatography | Profile | |
| Kimberly Cornwell | General Counsel | Profile | |
| Dianne Heiler | Senior Sustainability | Profile | |
| James Bylund | Chief Officer | Profile | |
| Kola Otitoju | Senior Development | Profile | |
| Stephen Tingley | VP Sales | Profile | |
| Jaime Humara | Senior Marketing | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.6 | Earnings Share 0.02 | Revenue Per Share | Quarterly Revenue Growth 0.219 | Return On Assets |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.